GAP and IMI to Sign MOU to Accelerate Alzheimer's Drug

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
GAP and IMI to Sign MOU to Accelerate Alzheimer's Drug Development

WASHINGTON and NICE, FRANCE, March 19, 2015 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform (GAP) and the Innovative Medicines Initiative (IMI) announced today that they will sign a Memorandum of Understanding (MOU) to accelerate Alzheimer's drug development by building a global, standing, trial-ready platform for Alzheimer's drug development. The collaboration represents a significant commitment to work together to recruit patients for clinical trials, to create a high-performing clinical trial system, and to develop a standing adaptive protocol to test new molecules quickly, and move those with promise into later stage development.

"This agreement represents an important commitment from major initiatives in Europe and the United States to expand and improve our capacity to conduct trials in Alzheimer's in order to bring innovative medicines to patients faster," said George Vradenburg, convener of the Global CEO Initiative on Alzheimer's Disease, co-founder of USAgainstAlzheimer's, and a member of the World Dementia Council. "Through our collaborative efforts here in the U.S., organized through GAP, and with these consortia in Europe, we believe we can begin to design a truly global clinical trial system of speed, power, and efficiency. No one company or one government can do this alone. We must have a global commitment and it must come from government, industry, and academia and be driven by the passion and urgency of the patient community."

Currently, there is no global pool of persons with or at risk of Alzheimer's who are standing ready, able, and willing to participate in clinical trials of promising innovative Alzheimer's medicines. The challenge of recruiting into the range of trials underway today and in the future stands as one of the single greatest barriers to increasing the pace of drug development in Alzheimer's. This problem is further compounded by the fact that each new Alzheimer's trial must start the process of participant recruitment and trial site preparation anew, with the consequence that lessons are lost, participant experience is wasted, and investments are repeated, costing individuals and industry precious time.

The Global Alzheimer's Platform , initiated by the Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences , is in advanced development with leadership and initial funding from Janssen Pharmaceuticals, the drug development division of Johnson and Johnson, Eli Lilly and Company, Lundbeck, Takeda, and The Ray and Dagmar Dolby Family Fund.  GAP's objectives are to establish a global standing, trial-ready platform, projected to reduce clinical testing cycle times by two years or more, to achieve greater efficiency and uniformity in trial populations through large, well-characterized trial-ready cohorts and certified clinical trial sites, and to more rapidly test the effectiveness of drugs through an adaptive proof of concept trial mechanism.  This platform will enable the delivery of efficient and effective proof of concept and confirmatory trials and ultimately the more rapid delivery of effective therapies to patients or those at risk.

The Innovative Medicines Initiative is a private-public partnership between the European Union (represented by the European Commission ) and the European pharmaceutical industry (represented by EFPIA , the European Federation of Pharmaceutical Industries and Associations) that aims to improve clinical trials success rate and deliver clinical proof of concept, biomarkers, and new medicines.

 "Alzheimer's disease is a global challenge that requires a global solution, and it is in this spirit that the IMI and GAP will collaborate and align their research.  The Memorandum of Understanding is the evidence for our genuine interest in working together to create an international clinical trials platform," said Irene Norstedt, IMI Acting Executive Director.  "Everyone working on Alzheimer's disease needs to pull together if we want to deliver results that will help us to end the suffering caused by this terrible disease."

"This collaboration has the potential to be a game changer for Alzheimer's drug development," said Dr. Janet Woodcock, Director of the Center for Drug Evaluation at the U.S. Food and Drug Administration.  "A global trial-ready platform will increase our prospects of finding important biomarkers, or discovering effective treatments for Alzheimer's.  If we don't do this, we may be facing decades of uncoordinated, one-off efforts that fail to enhance our ability to accelerate learning and human testing and really move the field forward."

Today's GAP-IMI announcement was made at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders taking place in Nice, France.  The meeting comes on the heels of the first-ever World Health Organization Ministerial Conference on Global Action Against Dementia, which took place in Geneva, Switzerland earlier this week.

"Lilly is pleased to see this level of global collaboration that aims to accelerate clinical trials and ultimately help speed drugs to patients," noted Phyllis Ferrell, global brand development leader, Alzheimer's disease at Eli Lilly and Company.  "We look forward to our continued work with GAP and IMI to assure the promise of this collaboration is realized."

Background on Alzheimer's

Alzheimer's disease is an incurable, progressive brain disease that slowly destroys memory and thinking skills and eventually is fatal.  Recent research indicates that Alzheimer's disease and dementia claims more than 500,000 lives in America annually, and more than 44 million worldwide.  The cost to care for Alzheimer's patients in the United States will exceed $1 trillion by 2050, according to USAgainstAlzheimer's, the organizer of CEOi.  Without a means of prevention or cure, the number of persons with Alzheimer's and dementia is projected to triple in size by 2050 and threaten the solvency of national health care systems the world over.  However, the scientific understanding of the disease continues to advance.  And there are several promising drug candidates now in development that potentially could benefit patients worldwide.  

Since the G8 Dementia Summit was held in London in December 2013, the global momentum in the response to Alzheimer's and dementia has grown tremendously.  This work includes the formation of the World Dementia Council; the convening of G8/G7 legacy meetings by Prime Minister Cameron of the United Kingdom, Health Minister Ambrose of Canada, and Prime Minister Abe of Japan; and the recognition by an increasing number of international organizations (United Nations, WHO, and the Organization for Economic Cooperation and Development) of the commitments needed to address the global challenge of Alzheimer's.  

The Global CEO Initiative on Alzheimer's Disease (CEOi) is an organization of private-sector leaders providing business leadership in the fight against Alzheimer's.  The CEO Initiative seeks to partner with political leaders to transform the disease from a social, health, and economic crisis into an opportunity for healthy aging and innovation in research and care.  The CEO Initiative believes that, during this era of aging populations, it will take visionary, united, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. Learn more at: www.ceoalzheimersinitiative.org .

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.  IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

New York Academy of Sciences (NYAS), founded in 1817, is one of the oldest scientific institutions in the U.S. with more than 20,000 members in 100 countries.  The Academy fosters new international collaborations among experts in academia, industry, and government to drive advances in science, medicine, technology, and sustainability, and is viewed as a global neutral convener, having formed international public private partnerships and aligning with the WHO to address the global challenges of under- and over-nutrition.  In 2011, the Academy expanded its portfolio of interdisciplinary scientific programs to launch the Alzheimer's Disease and Dementia Initiative (ADDI) that seeks to accelerate the transfer of basic research into the development of new methods to address Alzheimer's disease and dementia.  ADDI is committed to ensuring that there is coordinated action to develop improved diagnostics, preventive measures, and disease-modifying therapies for Alzheimer's disease and dementia. Please visit www.nyas.org/ADDI to learn more.

Ranit Schmelzer, 202-538-1065,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 113

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 107

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 100

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading

Top 5 Most Recently Viewed Articles

PLAY Airlines Achieves Record Load Factor and Revenue Growth

Updated Category News Views 271

PLAY Airlines Reports Record-Breaking Load Factor for November PLAY Airlines has announced that it carried an impressive 99,393 passengers in the month of November, showcasing its operational efficiency and strategic adaptations. Although this is a decrease from the 107,236 passengers flown in the same month in the previous year, this is largely attributed to a 17%...

Continue Reading
Exciting Drilling Results from U.S. GoldMining's Whistler Project

Updated Category News Views 101

U.S. GoldMining Reports Drilling Success at Whistler Project U.S. GoldMining Inc. (NASDAQ: USGO) has recently revealed initial results from its drilling activities at the Whistler Gold-Copper Project. This exciting announcement highlights the results from the first two diamond drill holes of the 2024 program. The drilling aims to expand on the previously identified...

Continue Reading
Trados Studio 2026: AI Innovations Elevate Translation

Updated Category News Views 82

Revolutionizing Translation: The Trados Studio 2026 Release It's barely out of the gate, and Trados Studio 2026 is already stirring the pot in the translation world. RWS, the company behind this game-changer, has loaded it with some serious tech muscle. Imagine turning a sluggish operation into a nimble powerhouse—well, that's the promise with the newest Trados Studio...

Continue Reading
Financial Institutions Innovate with Alternative Credit Data Insights

Updated Category News Views 210

Financial Institutions Innovate with Alternative Credit Data Insights Forty percent of financial institutions report rising delinquencies amid growing economic pressure. Recently, LexisNexis Risk Solutions shared the findings of its groundbreaking study on global consumer lending confidence, illustrating significant changes in how financial institutions assess consumer...

Continue Reading
Careviso Elevates Healthcare Access with Innovative COB Feature

Updated Category News Views 166

Careviso Unveils New Coordination of Benefits Feature Careviso, a leader in healthcare patient access technology, has introduced an innovative Coordination of Benefits (COB) feature in its seeQer platform and API. This feature aims to revolutionize the way healthcare organizations process multiple insurance coverages, ensuring that patients receive the most accurate...

Continue Reading